Unresectable gastric cancer with multiple liver metastases effectively treated with combined paclitaxel and doxifluridine chemotherapy

International Journal of Clinical Oncology

Volumn 11, Issue 6, 2006, Pages 471-474

  Mizutani, Shin ^a   Oyama, Tsukasa ^a   Hatanaka, Nobutaka ^a   Uchikoshi, Fumihiro ^a   Yoshidome, Katsuhide ^a   Tori, Masayuki ^a   Ueshima, Shigeyuki ^a   Nakahara, Masaaki ^a   Nakao, Kazuyasu ^a  

^a OSAKA POLICE HOSPITAL   (Japan)

Author keywords

Combined chemotherapy; Doxifluridine; Multiple liver metastases; Paclitaxel; Unresectable gastric cancer

Indexed keywords

ANTIEMETIC AGENT; CA 19-9 ANTIGEN; CARCINOEMBRYONIC ANTIGEN; DEXAMETHASONE; DIPHENHYDRAMINE; DOXIFLURIDINE; PACLITAXEL; RANITIDINE; TUMOR MARKER;

ABDOMINAL RADIOGRAPHY; ADVANCED CANCER; AGED; ANOREXIA; ARTICLE; BLOOD LEVEL; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER SIZE; CASE REPORT; CLINICAL EXAMINATION; CLINICAL FEATURE; COMPUTER ASSISTED TOMOGRAPHY; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG INFUSION; DRUG RESPONSE; GASTROSCOPY; HUMAN; LEUKOCYTE COUNT; LIVER METASTASIS; LYMPHADENOPATHY; MALE; MULTIPLE CYCLE TREATMENT; PARAAORTIC LYMPH NODE; PRIORITY JOURNAL; SIDE EFFECT; STOMACH ADENOCARCINOMA; STOMACH WALL; THROMBOCYTE COUNT; TREATMENT OUTCOME;

AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; FLOXURIDINE; HUMANS; LIVER NEOPLASMS; MALE; PACLITAXEL; STOMACH NEOPLASMS; TREATMENT OUTCOME;

EID: 33845764817     PISSN: 13419625     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10147-006-0597-y     Document Type: Article

References (14)

1. Y Yamada K Shirao A Ohtsu 2001 Phase II trial of paclitaxel by 3-h infusion for advanced gastric cancer with short premedication for prophylaxis against paclitaxel-associated hypersensitivity reaction Ann Oncol 12 1133 1137
2. AD Seidman CA Hudis J Albanel 1998 Dose-dense therapy with weekly 1-h paclitaxel infusions in the treatment of metastatic breast cancer J Clin Oncol 16 3353 3361
3. T Arai T Hamaguchi K Shirao 2003 Weekly paclitaxel (PTX) in patients with heavily treated advanced gastric cancer Jpn J Cancer Clin 49 621 625
4. P Therasse SG Arbuck EA Eisenhauer 2000 New guidelines to evaluate the response to treatment in solid tumors J Natl Cancer Inst 92 205 216
5. PB Schiff SB Horwitz 1981 Taxol assembles tubulin in the absence of exogenous guanosine 5′-triphosphate or microtubule-associated protein Biochemistry 20 3247 3252
6. P Rosenberg H Andersson K Boman 2002 Randomized trial of single agent paclitaxel given weekly versus every 3 weeks and with peroral versus intravenous steroid premedication to patients with ovarian cancer previously treated with platinum Acta Oncol 41 418 424
7. A Seidman D Berry C Cirrincione 2004 Phase III study of weekly paclitaxel via 1-h infusion vs standard 3-h infusion every third week in the treatment of metastatic breast cancer, with trastuzumab for HER2 + MBC and randomized for trastuzumab for HER2 normal MBC Proc ASCO 23 abstract 512
8. S Yamamoto Y Tanaka T Ito 2003 Weekly paclitaxel for a patient with advanced gastric cancer Gastric Cancer 6 117 121
9. Y Sakurai I Yoshida S Tonomura 2003 Weekly administration of paclitaxel attenuated rectal stenosis caused by multiple peritoneal recurrence 8 years after the resection of gastric carcinoma Gastric Cancer 6 243 249
10. A Kono Y Hara S Sugata 1983 Activation of 5′-deoxy-5-fluorouridine by thymidine phosphorylase in human tumors Chem Pharm Bull 31 175 178
11. N Sawada T Ishikawa Y Fukase 1998 Induction of thymidine phosphorylase activity and enhancement of capecitabine efficacy by taxol/taxotere in human cancer xenografts Clin Cancer Res 4 1013 1019
12. K Fujimoto-Ouchi Y Tanaka T Tominaga 2001 Schedule dependency of antitumor activity in combination therapy with capecitabine/5′-deoxy-5- fluorouridine and docetaxel in breast cancer models Clin Cancer Res 7 1079 1086
13. I Takeyoshi F Makita Y Tanahashi 2005 A combination phase I study of weekly paclitaxel and doxifluridine in advanced gastric cancer patients Anticancer Res 25 1291 1296
14. S Yoshino M Oka S Hazama 2004 A combination phase I study of weekly paclitaxel and 5′-DFUR in patients with unresectable or recurrent gastric cancer in an outpatient setting Proc ASCO 23 abstract 4228